Neuropathic pain in the general population: a systematic review of epidemiological studies. by van Hecke, O. et al.
VAN HECKE, O., AUSTIN, S.K., KHAN, R.A., SMITH, B.H. and TORRANCE, N. 2014. Neuropathic pain in the general 
population: a systematic review of epidemiological studies. Pain [online], 155(4), pages 654-662. Available from: 
https://doi.org/10.1016/j.pain.2013.11.013 
Neuropathic pain in the general population: a 
systematic review of epidemiological studies. 
VAN HECKE, O., AUSTIN, S.K., KHAN, R.A., SMITH, B.H. and    
TORRANCE, N.  
2014 
This document was downloaded from 
https://openair.rgu.ac.uk 
 
Neuropathic pain in the general population: a systematic review of epidemiological 
studies 
O. van Hecke a,⇑, Sophie K. Austin b, Rafi A. Khan c, B.H. Smith a, N. Torrance a 
a Medical Research Institute, University of Dundee, UK 
b Foundation Year, Livingston Hospital, NHS Lothian, Livingston, UK 
c Department of Anaesthesia, Ninewells Hospital and Medical School, Dundee, UK 
 
 
Abstract 
 
Most patients with neuropathic pain symptoms present and are managed in primary care, with only a minority 
being referred for specialist clinical assessment and diagnoses.  Previous reviews have focused mainly on specific 
neuropathic pain conditions based in specialist settings. This is the first systematic review of epidemiological 
studies of neuropathic pain in the general population. Electronic databases were searched from January 1966 to 
December 2012, and studies were included where the main focus was on neuropathic pain prevalence and/or 
incidence, either as part of a specific neuropathic pain-related condition or as a global entity in the general 
population. We excluded studies in which data were extracted from pain or other specialist clinics or focusing on 
specific population subgroups. Twenty-one articles were identified and underwent quality assessment and data 
extraction. Included studies differed in 3 main ways: method of data retrieval, case ascertainment tool used, and 
presentation of prevalence/incidence rates. This heterogeneity precluded any meta-analysis. We categorised 
comparable incidence and prevalence rates into 2 main subgroups: (1) chronic pain with neuropathic 
characteristics (range 3–17%), and (2)  neuropathic pain associated with a specific condition, including 
postherpetic neuralgia (3.9–42.0/100,000 person–years [PY]), trigeminal neuralgia (12.6–28.9/100,000 PY), painful 
diabetic peripheral neuropathy (15.3–72.3/100,000 PY), glossopharyngeal neuralgia (0.2–0.4/100,000 PY). These 
differences highlight the importance of a standardised approach for identifying neuropathic pain in future 
epidemiological studies.  A best estimate of population prevalence of  pain with neuropathic characteristics is 
likely to lie between 6.9% and 10%. 
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1. Introduction 
 
Neuropathic pain is widely recognised as one of the most difficult pain syndromes to manage, and outcomes 
often are unsatisfactory. This is partly because the contribution of neuropathy to pain presenting in primary 
care may be unrecognized [2,10] and there is evidence of suboptimal drug use in the treatment of neuropathic 
pain [12,36,37]. Epidemiological research in this area can be problematic, and the reasons for this are 
multifactorial: the lack of agreed, valid case definitions that truly reflect the condition(s) under consideration 
and that are feasible to apply in population-based studies; heterogeneous studies of variable quality, using 
different means of case ascertainment; and inclusion or exclusion of cases in which pain is not a primary 
presenting complaint [10]. Existing estimates of the general population prevalence therefore vary widely, and it is 
likely that more people experience neuropathic symptoms than have been diagnosed with a neuropathic pain-
related condition [11]. 
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Population-based estimates of neuropathic pain prevalence are important in order to determine resource 
requirements (clinical, financial, educational) for primary care, where most people with chronic pain are treated 
and managed, and to inform the targeting of treatment and prevention strategies [17]. As validated screening 
tools to identify neuropathic pain have been developed [3,34], these have enabled questionnaire-based 
epidemiological studies, and there is a growing body of literature exploring the epidemiology of neuropathic 
pain symptoms and conditions in the community. We conducted a systematic search and structured literature 
review of the epidemiology of neuropathic pain in the general population and aimed to provide, where possible, 
estimates of incidence and prevalence. 
 
 
 
2. Methods 
 
2.1. Study selection 
 
A comprehensive search strategy was developed to identify all articles reporting population-based studies 
of the epidemiology  of neuropathic pain (see Supplementary Materials). Electronic databases MEDLINE, 
EMBASE, ISI Web of Science, and CINAHL were searched from January 1966 to December 2012 for English-
language articles that fulfilled the inclusion/exclusion criteria. We included studies in which (1) the main focus 
was on neuropathic pain, either as part of a specific clinical condition or as a global clinical entity; (2) the core 
emphasis was on incidence and/or prevalence of neuropathic pain; and (3) the study sample was reasonably 
representative of the general population (thus including studies conducted in primary care/general practice 
populations where these approximated to general population samples). Article titles were reviewed to 
determine those that obviously did not meet the inclusion criteria and those that were required assessment in 
greater depth. 
Excluded articles were those in which data were specifically obtained from pain or other specialist clinics, 
those that focused on specific population subgroups (eg, age, gender, occupation, ethnicity), and review articles 
(although reference lists of these were hand-searched for additional relevant studies). A grey literature search 
was performed after completion of the main search, seeking articles from conference proceedings and meetings 
on the ISI Web of Science database. 
 
2.2. Data extraction 
 
The database searches were conducted by S.A. and R.A.K. Titles were reviewed for possible inclusion, 
then abstracts examined, before the full-text version of the remaining articles were obtained. All authors 
were involved in various stages throughout this process and in the final selection and data extraction of 
included articles (Table 1). We extracted data on study characteristics (country, study design, and method 
of data retrieval); the sample size and number of patients with neuropathic pain in the sample population; 
case ascertainment instrument or tool used to identify the neuropathic pain condition; and the specific 
condition or disease associated with neuropathic pain. 
 
2.3. Quality assessment 
 
All articles that fully met the inclusion criteria were critically appraised using the STROBE checklist 
(STrengthening the Reporting of OBservational studies in Epidemiology)  [40]. This is a structured, 
standardised checklist consisting of 22 items, each relating to the different sections in an article (ie, title, abstract, 
introduction, methods, results, discussion, and funding) with the main purpose being to  improve  the 
transparency of reporting in epidemiological observational research [40]. 
Quality factors based on key items of the STROBE quality checklist instrument were combined to form a 
modified checklist consisting of a total of 30 items with a simple point system.  Each article was then given a 
total score out of 30. The quality scores calculated for each article gave comparisons of the relative quality of 
included studies, a higher score indicating higher quality. A relatively low score did not necessarily imply poor-
quality research, as the score was a guide to the quality of reporting according to  a specific (STROBE) checklist. 
 
2.4. Analysis 
 
We aimed to compare the prevalence and incidence rates of specific neuropathic pain diagnoses, and/or of 
neuropathic pain as a global clinical entity. 
 
3. Results 
 
Fig. 1 shows the results of the article selection process. 
 
3.1. Characteristics of studies 
 
We identified 3826 articles from the electronic searches after removal of duplicates (Fig. 1). These articles 
were then reviewed by title, abstract, and full-text review and either included or excluded based on the 
selection criteria. Of these, 21 articles fulfilled the inclusion criteria and underwent quality assessment and 
data extraction and were included in the final review. 
Fourteen studies were based in single European countries [4,7,9,10,13–15,18,19,24,26,30,32,35], 4 studies 
were based in the United States [6,22,23,42], and the remaining studies were each conducted in Brazil [8], 
Taiwan (China) [21], and Canada [38]. 
A wide variety of study designs was identified by the systematic review. There are 3 main ways in which the 
studies seemed to differ: first, in the method of data retrieval; secondly, in the case ascertainment tool used; 
and finally, in the presentation of the prevalence/incidence rates found. In order to make sense of the data, and 
to present results appropriately, it is important to take these factors into account. 
 
3.1.1. Data presentation of the prevalence/incidence rates 
Some studies focused on identifying rates of neuropathic pain that was a characteristic of chronic pain, 
whereas other studies reported rates of a clinical condition or disease associated with neuropathic pain. Due to 
the heterogeneity of included studies as noted earlier, the prevalence or incidence rates cannot be simply 
combined for meta-analysis. For this reason, we have categorised the incidence and prevalence rates into 
chronic pain with neuropathic characteristics or of neuropathic origin and neuropathic pain associated with a 
specific disease or  condition. 
 
3.1.2. Method of data retrieval 
Data retrieval was either by electronic database searching or use of research questionnaires. Of the final 21 
articles identified (Fig. 1), 14 studies were conducted using a database or primary care medical records, 6 
studies were conducted by questionnaire or survey, and 1 study used a combination of both methods (Table 
1). 
 
3.1.3. Case ascertainment of neuropathic pain 
A number of different ways of identifying cases were found. Generally, studies based on research 
questionnaires used validated case ascertainment tools such as the Douleur Neuropathique en 4 questions 
(DN4) [5] or the Self complete Leeds Assessment of Neuropathic Symptoms & Signs (S-LANSS) [1], whereas 
studies that extracted data from databases relied on coding systems, such as the Oxford Medical Information 
System (OXMIS) classification [19] or the International Classification of Primary Care (ICPC) coding system 
[41] to identify cases. 
As shown in Table 1, most studies included either incidence or prevalence rates, and 1 provided both [26]. 
Four studies did not provide specific incidence or prevalence rates [6,7,9,30]. However, these studies did 
provide sufficient information from which a prevalence or incidence rate could be calculated. 
 
 
 
Table 1 
Epidemiology of pain with neuropathic characteristics in the general population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Classification of 4 criteria in tex 
• Specialist review 
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Study Country Study design and method 
of data retrieval 
Sample size 
(response 
NeuP cases 
identified 
NeuP case ascertainment method/ 
instrument 
NeuP condition Incidence 
estimates 
Prevalence 
estimates 
Quality assessment 
score (maximum 
   rate)    [95% CI] [95% CI] 30)* 
Bouhassira et al. (2008) France Postal survey 23,712 1631 Self-administered DN4 Chronic pain with N/A 6.9% 26 
   (81.2%)   neuropathic  [6.6%–7.2%]  
      characteristics (NeuP)    
Choo et al. (1997) United Automated medical 250,000 66 (at 30 No standardised tool; clinical diagnosis PHN (more than 60 days 0.007% at 60 days N/A 27 
 States records review, claims  days) (recorded or likely) after HZ) (4.5% of HZV)   
  and pharmacy records  37 (at 60      
    days)      
Davies et al. (2006) UK Cross-sectional postal 8531 71t Screening: 1x item diabetic neuropathy PDPN N/A Overall 21 
  survey and neurological (92.7%)  symptom score)   prevalence: 0.8%t  
  examination   PDPN: clinical examination using     
     Toronto Clinical Scoring System     
De Moraes Vieira (2012) Brazil Cross-sectional interview 1597 157 Validated DN4 (Portuguese) and DN4- NeuP N/A 10% No 95% CI 27 
  survey and physical   based physical examination   reported  
  examination        
Dieleman et al. (2008) Netherlands General practice research 362,693 9135 (all Free text search and ICPC coding Neuropathic pain 8.2/1000 PY [8.0– N/A 25 
  database, cohort study  NeuP) determine diagnosis, then manual review PHN 8.4]   
    322 (TN) of electronic patient records TN 41.8/100,000 PY   
    4 (GN)  GN [38.1–45.7]   
       28.9/100,000 PY   
       [25.8–32.1]   
       0.40/100,000 PY   
       [0.1–0.9]   
Gajria et al. (2011) UK Computerised medical 105,877 1390 33 coded diagnosis of conditions in Chronic pain with NeuP N/A 1.3% 24 
  records review   medical records (READ codes) associated   No 95% CI reported  
     with NeuP     
Gore et al. (2007) UK General practice research 1.9 million 16,690 Coded diagnosis of conditions (OXMIS Predominate NeuP N/A 0.9% 17 
  database   and READ codes)   No 95% CI reported  
Gustorff et al. (2007) Austria Internet-based, 7707 260 Selected items from LANSS (part A) and Neuropathic pain N/A 3.3% 16 
  prospective   DN4   No 95% CI reported  
  representative survey        
Hall et al. (2006) UK General practice research >6.8 million PHN: 12,386 Coded diagnosis of conditions (OXMIS PHN 40.2/100,000 PY N/A 21 
  database  TN: 8268 and READ codes) TN [39.5–40.9]   
    PLP: 451  PLP 26.8/100,000 PY   
    PDPN: 4719  PDPN [26.2–27.4]   
       1.5/100,000 PY   
       [1.3–1.6]   
       15.3/100,000 PY   
       [14.9–15.7]   
Hall et al. (2008) UK Computerised database of >2.9 million PHN: 1923 Coded diagnosis of conditions (OXMIS PHN Age-standardised N/A 19 
  primary care records  TN: 1862 and READ codes) TN 27.3/100,000 PY   
  (THIN database)  PLP: 57  PLP [27.0–29.5]   
    PDPN: 1867  PDPN 26.7/100,000 PY   
       [26.1–28.6]   
       0.8/100,000 PY   
       [0.6–1.1]   
       26.7/100,000 PY   
       [26.0–28.4]   
Jih et al. (2009) Taiwan National Health 1 million 4543 (30 No standardised tool; PHN 42.0/100,000 PYk N/A 24 
  Insurance electronic  days) ICPC code for HZ.  No 95% CI   
  database, retrospective 
cohort study 
 2944 (90 
days)§ 
PHN defined as revisit >90 days after 
onset or treatment 
 reported   
Katusic et al. (1990) United Medical records 222 75 Rushton and Olafson criteria for TN TN 4.7 per 100,000 N/A 20 
 States    Specialist review  population [3.6–   
       5.8]   
Katusic et al. (1991) United 
States 
Medical records 238 12 • No standardised definition GN 0.8 per 100,000 
population [0.3– 
N/A 18 
 
 
 
 
Koopman et al. (2009) Netherlands General practice research 
database 
193,838 362 • Facial pain: IASP criteria 
(probable/possible) 
• Specialists review random 
sample possible cases 
Overall 
PHN 
TN 
GN 
38.7/100,000 PY 
[34.9–42.9] 
3.9/100,000 PY 
[2.7–5.3] 
12.6/100,000 PY 
[10.5–15.1] 
0.2/100,000 PY 
[0.0–0.7] 
N/A 26 
Di Luzio Paparatti et al. 
(1999) 
Italy Medical records, 
retrospective study 
98,508 Not provided No standardised tool; PHN defined within 
text (at least 1 month after HZV) 
PHN N/A 0.09%– 17 
No 95% CI reported 
MacDonald  et al. (2000) UK Database and 
examination prospective 
study 
100,230 Not provided Multiple methods PHN 
TN 
11/100,000/ year 
[6.0–17.0] 
8.0 /100,000/year 
[4.0–13.0] 
0.7 per 1000 [0.4– 23 
1.0] 
0.7 per 1000 [0.4– 
1.0] 
Opstelten  et al. (2002) Netherlands      Computerised medical 
records review (GPRD) 
~49,000 837 No standardised tool; coded and free text 
diagnosis of HZV and PHN 
PHN 0.009%/ 
population/year 
N/A 17 
Pierik et al. (2012) Netherlands Retrospective cohort 
study (2004-2008) 
~165,000 195 (PHN) 
75 (TN) 
24 (facial 
pain) 
ICPC code for varicella, and HZ and 
noncoded information 
Overall (all ages) 
PHN 
TN 
Facial pain 
47.5 per 10, 000 
[40.6–54.4] 
5.8% [5.0–6.6] 
2.2% [1.71–2.71] 
N/A 25 
States records, telephone 
interview, and clinical 
examination 
(61.0%) 
 
 
 
 
 
examination: 
75/205 
S-LANSS: 
315/3575 
Berger 
criteria: 
107/3575 
Self-reported: 
443/3575 
 
 
 
 
 
1. IASP criteria (clinical 
examination) 
2. S-LANSS (postal) 
3. Berger criteria (medical records) 
 
 
 
 
 
examination: 9.8% 
[6.2%–13.4%] 
S-LANSS: 8.8% 
[7.9%–9.8%] 
Berger criteria: 
3.0% [2.5%–3.6%] 
Self-reported: 
12.4% [11.4%– 
13.6%] 
 
 
NeuP, neuropathic pain; DN4, Douleur Neuropathique en 4 questions; N/A, not applicable, CI, confidence interval; PHN, postherpetic neuralgia; HZ, herpes zoster; HZV, Herpes Zoster Virus; PDPN, painful diabetic peripheral 
neuropathy; TN, trigeminal neuralgia; GN, glossopharyngeal neuralgia; ICPC, The International Classification of Primary Care; PY, Person-years; READ, Coded thesaurus of  clinical terms which  enables clinicians  to make effective  use 
of computers systems for use in General practice; OXMIS, Oxford Medical Information System; LANSS, Leeds Assessment of Neuropathic Symptoms & Signs; THIN, The Health Improvement Network; IASP, International Association 
for the Study of Pain; GPRD, General Practice Research Database ; ICPC, International Classification of Primary Care; S-LANSS, Self-complete Leeds Assessment of Neuropathic Symptoms & Signs. 
* Based on STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) checklist for reporting of observational studies (higher score correlating with higher quality). 
t Mixed PDPN included. 
t Prevalence of 26.4% of PDPN in those with type 2 diabetes who responded positively to screening question and attended for assessment. 
k PHN incidence calculated at 90 days (3 months). 
§ Original reported as 0.42 per 1000 PY. 
– Calculation extrapolated: (21.4% of 408)/98,508. 
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Torrance et al. (2006) 
 
UK 
 
Cross-sectional postal 
 
3002 
 
241 
 
S-LANSS 
 
Pain of predominate 
0.7% [0.41–0.97] 
N/A 
 
8.2% [7.2%–9.2%] 
 
26 
  survey (52.4%)   neuropathic origin    
Toth et al. (2009) Canada Telephone-based survey 1207 Not provided DN4 Chronic pain with N/A 17.9% [15.8%– 25 
   (42.5%)   neuropathic symptoms  20.2%]  
Yawn et al. (2009) United Postal survey, medical 3575 Clinical Multiple: NeuP N/A Clinical 22 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. PRISMA flow chart. 
 
 
3.2. Results for studies on chronic pain with neuropathic characteristics or pain of predominantly neuropathic origin 
 
3.2.1. Prevalence 
 
Eight studies measured chronic pain with neuropathic (or ‘predominantly neuropathic’) characteristics 
[4,8,13–15,35,38,42]. The prevalence rates of neuropathic pain as a global clinical entity ranged from 0.9% to 17.9% 
(Table 2). All of these studies retrieved data by a postal questionnaire or telephone survey, with the exception of 
the studies by Gajria [13] (2011) and Gore et al. [14] (2007), which identified neuropathic cases from electronic 
databases.  The DN4 case ascertainment tool was used by Bouhassira et al. [4] (2008), De Moraes Vieira et al. 
[8] (2012), and Toth et al. [38] (2009). The former 2 had comparable prevalence rates. Toth et al. [38] (2009) had 
a prevalence rate that was considerably higher. Gustorff et al. [15] (2007) used LANSS (part A), whereas Torrance 
et al. [35] (2006) and Yawn et al. [42] (2009) used the S-LANSS, and both studies found similar prevalence rates. 
 
3.2.2. Incidence 
Dieleman et al. [10] (2008) was the only study included. Reported incidence rates for a number of conditions 
associated with neuropathic pain were obtained, with an overall incidence rate in the general/study population 
of neuropathic pain of 8.2 per 1000 person–years [95% confidence interval 8.0–8.4] (Table 2). 
 
 
 
 
 
 
 
 
 3.3. Results for studies on neuropathic pain associated with a specific condition or disease 
 
A number of studies reported rates of a clinical condition or disease strongly associated with neuropathic pain 
[6,7,9,10,18,19, 21–24,26,30,32]. The main conditions or diseases identified were postherpetic neuralgia (PHN), 
trigeminal neuralgia (TN), painful diabetic peripheral neuropathy (PDPN), and glossopharyngeal neuralgia 
(GN). Others conditions mentioned were phantom limb pain (PLP) and facial pain. Their prevalence and 
incidence rates are summarised in Tables 3 and 4. 
These studies were almost all database retrieval studies. A wide variety of case identification methods was 
used, often involving a number of different steps to verify the cases identified. For example, researchers in the 
study by Koopman et al. [24] used a 2-step process of case ascertainment: first, the researchers used the 
International Association for the Study of  Pain (IASP) case definition criteria to search the database for different 
facial pain conditions associated with neuropathic pain and classed as either probable, possible, or no neuropathic 
pain; all probable cases were reviewed by a second medical doctor and discrepancies were arbitrated by a pain 
specialist. Secondly, additional information from the patients’ medical records was sought to verify all possible 
cases. 
 
3.3.1. PHN 
Prevalence rates of PHN were reported in 2 included studies [9,26]. They ranged from 0.09% per annum 
and 0.7 per 1000 (Table 4). The study by Di Luzio Paparatti et al. [9] contained missing data. They reported 
that 408 of the 95,508 patients in their population had herpes zoster (HZ); however, only 322 of those were 
screened for complications. Of those screened, 21.4% had PHN. For the purposes of this analysis, we 
assumed that the rate for those screened was the same as for those not screened. The prevalence therefore 
was   calculated by the equation [(408* 21.4)/98,508]. 
 
The incidence rates of PHN were reported in 9 studies [6,10,18,19,21,24,26,30,32]. Note that some articles 
calculated incidence rates in percent of population per year [6,30,32], whereas others reported per 100,000 person–
years  [10,18,19,21,24], and one reported number per population per year [26]. For this reason, direct comparisons 
could not be made among all studies. For those that were comparable, rates ranged from 3.9/100,000 person–years 
to 42.0/100,000 person–years (Table 3). 
The study by Opstelten et al. [30] (2002) was calculated from the data provided over a 5-year period, and the 
number in the total study population varied from year to year. Of the 837 individuals with HZ, 2.6% had persistent 
pain after 3 months. As the overall population was reported to be approximately 49,000, the rate was calculated 
by the equation: [(2.6* 837)/49,000)] over 5 years; dividing the answer by 5 found the incidence rate per population 
per year. A similar method was used in the study by Pierik et al. [32] to calculate the incidence. 
The study by Choo et al. [6] (1997) had reported a prevalence of PHN among those who had experienced HZ 
in a general population said to number 250,000. In fact, it was incidence that they calculated. There were 37 cases 
of PHN identified >60 days after HZ infection. The rate of PHN in the general population was recalculated using 
the equation [37/250,000] and divided over 2 years. 
 
Table 2 
Prevalence and incidence of chronic pain with neuropathic features and method of case ascertainment. 
Prevalence rate,% [95% CI] Author and year of publication Case ascertainment tool 
6.9 
[6.6–7.2] 
10 
No reported CI 
17.9 
[15.8–20.2] 
8.2 
[7.2–9.2] 
Clinical examination: 9.8% 
[6.2–13.4] 
S-L ANSS: 8.8% 
[7.9–9.8] 
Berger criteria: 3.0% 
[2.5–3.6] 
Self-reported: 12.4% 
[11.4–13.6] 
Bouhassira  et al. (2008) DN4 
 
De Moraes Vieira et al. (2012) DN4 
 
Toth  et al. (2009) DN4 
 
Torrance  et al. (2006) S-LANSS 
 
Yawn  et al. (2009) Multiple 
• Clinical examination 
• S-LANSS 
• Berger criteria 
• Self-reported 
3.3No reported CI Gustorff et al. (2007) Selected items from LANSS (part A) and DN4, and additional questions 
Prevalence rate,%[95% CI] Author and year of publication Cases coded from electronic databases 
1.3No reported CI Gajria  et al. (2011) Coded diagnosis (READ codes) 
0.9No reported CI Gore  et al. (2007) Coded diagnosis (OXMIS and READ codes) 
Incidence rate [95% CI] 
8.2 /1000 person–years[8.0–8.4] Dieleman  et al. (2008) Multiple 
• Free text search and ICPC coding 
  • Manual review of electronic patient records  
DN4, Doleur Neuropathique en 4 questions; OXMIS, Oxford Medical Information System; S-LANSS, Self-complete Leeds Assessment of Neuropathic Symptoms & Signs; ICPC, 
International Classification of Primary Care. 
 
Table 3 
Incidence of neuropathic pain associated with a specific condition or disease. 
 
Condition or disease Incidence rate* Reference Funding sourcet 
Postherpetic neuralgia 41.8 per 100,000 PY Dieleman et al. (2008) 2 
 40.2 per 100,000 PY Hall et al. (2006) 3 
 28.2 per 100,000 PY Hall et al. (2008) 3 
 42.0 per 100,000 PYt Jih et al. (2009) 1 
 3.9 per 100,000 PY Koopman et al. (2009) 2 
 11.0/100,000/year MacDonald et al. (2000) 1 
 0.007%/population/year Choo et al. (1997) 2 
 0.009%/population/year Opstelten et al. (2002) 1 
 0.024%/population/year§ Pierik et al. (2012)k 3 
Trigeminal neuralgia 28.9 per 100,000 PY Dieleman et al. (2008) 2 
 26.8 per 100,000 PY Hall et al. (2006) 3 
 27.3 per 100,000 PY Hall et al. (2008) 3 
 12.6 per 100,000 PY Koopman et al. (2009) 2 
 4.7 per 100,000 population Katusic et al. (1990) 1 
 8.0/100,000/year MacDonald et al. (2000) 1 
 0.009%/population/yeare– Pierik et al. (2012)k 3 
Glossopharyngeal neuralgia 0.4 per 100,000PY Dieleman et al. (2008) 2 
 0.8 per 100,000 population Katusic et al. (1991) 1 
 0.2 per 100,000 PY Koopman et al. (2009) 2 
Phantom limb pain 1.5 per 100,000 PY Hall et al. (2006) 3 
 0.8 per 100,000 PY Hall et al. (2008) 3 
Painful diabetic peripheral neuropathy 72.3 per 100,000 PY Dieleman et al. (2008) 2 
 15.3 per 100,000 PY Hall et al. (2006) 3 
 27.2 per 100,000 PY Hall et al. (2008) 3 
PY, person–years. 
* Most incidence rates are calculated in person–years. This form of rate takes into consideration the dynamic nature of the population and allows direct comparisons in 
different populations. 
t Funding supported by: 1, government/charity/non-profit organisation; 2, educational grant from pharmaceutical industry, no industry authors; 3, pharmaceutical industry 
funded and industry author included. 
t Extrapolated from 0.42/1000 PY. 
§ Calculated: 195/165,000 over 5-year period *100 (%). 
k Age-standardised incidence rate. 
– Calculated: 75/165,000 over 5-year period * 100 (%). 
 
 Table 4 
Prevalence of neuropathic pain associated with a specific condition or disease. 
     Condition/disease ..........  Prevalence rate [95% 
confidence interval] 
 
Reference 
 
     Postherpetic neuralgia  0.09% 
No CI reported 
0.7 per 1000 [0.4-1.0] 
Di Luzio 
Paparatti et al. 
      Trigeminal neuralgia 0.7 per 1000 [0.4-1.0] MacDonald      
et al. 
      Painful diabetic peripheral 
neuropathy 
0.8%* 
[0.02-0.14]* 
Davies et al. 
 
* Extrapolated: 71/8531 * 100; confidence intervals calculated. 
 
 
 
3.3.2. TN 
Incidence rates of TN were reported in 7 studies [10,18,19,22,24,26,32]. Comparable rates ranged from 
12.6/100,000 person–years to 28.9/100,000 person–years (Table 3). 
 
3.3.3. PDPN 
The population prevalence of PDPN was calculated at 0.8%, representing 26.4% of those with type 2 diabetes 
who responded positively to screening questions and attended clinical assessment (Table 4). Incidence rates of 
PDPN were reported in 3 studies [10,18,19]. Rates ranged from 15.3/100,000 person–years to 72.3/100,000 
person–years (Table 3). PHN, TN, and PDPN had the highest incidence rates, compared to GN and PLP. 
 
3.4. Funding of included studies 
 
We identified 3 main sources of funding for the research. Some studies were funded by government, charity, 
or nonprofit organisations [8,15,21–23,26,30,38]; others had educational grants from industry but no authorship 
[4,6,7,10,24,35,42]; and the remainder were conducted and/or supported by pharmaceutical industry and had 
declared authorship [9,13,14,18,19,32]. There were no apparent systematic differences in study results associated 
with the source of funding. 
 
4. Discussion 
 
This is the first comprehensive systematic literature review of epidemiological studies of neuropathic pain in 
the general population. Rather than a traditional systematic review of randomised controlled trials, this review 
is based on observational studies within the general population using recently standardised methodology [31,40]. 
The heterogeneity between the identified studies precluded meta-analysis and calculation of combined estimates 
of prevalence and/or incidence rates of neuropathic pain. Nevertheless, we are able to draw comparisons 
between different studies and conditions and to consider these in the context of the relative quality, strengths 
and weaknesses, and study designs and reporting. 
 
4.1. Main findings 
 
Overall, the prevalence of neuropathic pain as a feature of chronic pain (or pain of predominantly 
neuropathic origin) was examined by 8 studies and ranged from 1% to 17.9% (Table 21). In studies that used 
questionnaire-based case ascertainment tools such as DN4 and S-LANSS, the range of prevalence estimates was 
wide (3.3-17.9%). However, including only studies that administered case ascertainment tools precisely as they 
were designed and validated, the range of prevalence rates was much narrower (6.9–10%) [4,8,35,42]. 
Gustorff et al. [15] utilised the LANSS (Part A) along with additional pain questions and some specific 
exclusion criteria, limiting their analysis to people with a known underlying neuropathic pain diagnosis 
(people with exclusive joint pain or reported rheumatism, migraine, fibromyalgia, visceral pain, and/or 
satisfying  
 
 
 
 
response to over-the-counter analgesic medication were excluded from further interview, as well as people 
suffering from an undifferentiated cause as the main cause of their pain); this explains their estimate of the 
lowest prevalence of neuropathic pain at 3.3%.  
In contrast, Toth et al. [8] included all respondents who reported ‘‘daily or near daily pain’’ from telephone 
surveys of the general population in a Canadian province (finding a prevalence of 38%). Respondents then 
completed the DN4, with a resultant highest prevalence estimate of neuropathic pain at 17.9%. This is likely 
an overestimate due to the screening question used to identify the presence of pain or selection bias in the 
underlying population. Other studies, utilising data obtained from computerised medical records, found a 
much lower overall prevalence of around 1% [13,14]. This lower rate likely reflects differences in case 
ascertainment, and in particular that electronic records can only identify patients who have presented to 
primary care and had a diagnosis recorded by the attending physician. 
When we examined studies of specific neuropathic pain conditions, most of them reported incidence rates per 
person–years, which is a useful parameter for comparing rates, although less clinically useful as a direct indicator 
of the number of cases likely to arise in a specific population during a specific period. Koopman et al. [24] 
consistently reported lower incidence rates of PHN, TN, and GN (Table 3) than the other studies, and this is 
mostly likely due to differences in case ascertainment.  This can be illustrated by comparing this study with that 
reported by Dieleman et al. [10]. Both of these studies were conducted in consecutive years and both used the 
IPCI database in the Netherlands, yet they found very different incidence rates. For example, looking at TN, 
Koopman et al. reported an incidence rate of 12.6/100,000 person–years, whereas Dieleman et al. reported a rate 
of 28.9/100,000 person years. Koopman et al. accessed additional information when identifying the cases, and 
the authors were able to identify and then to exclude misclassified cases (false-positive cases) from the analysis. 
As a result, the authors suggest their estimate of the incidence of TN was less likely to be exaggerated due to 
misclassification. 
Because of the heterogeneity of included studies, it is not possible to calculate a valid weighted prevalence or 
incidence for any neuropathic pain condition. Therefore, based on the quality, methods, and other characteristics 
of the studies we reviewed, and acknowledging this heterogeneity, a best-estimate range of comparable incidence 
rates for PHN is potentially narrower (28.2–42.0/100,000  person–years)  [10,18,19,21],  and  similar  for TN (26.8–
28.9/100,000 person–years) [10,18,19], GN (0.4–0.8/100,000 person–years) [10,23], and PLP (0.8–1.5/100,000 
person–years) [18,19]. The incidence range of PDPN remains wide (15.3–72.3/100,000 person–years) [10,18,19] 
despite comparable incidence rates for PHN and TN. Irrespective of these differences, it seems clear that GN and 
PLP occur much less frequently than PDPN or PHN. 
 
4.2. Other findings 
 
It was surprising that some articles did not provide a working definition for neuropathic pain as a starting point. 
The articles that did include a definition cited the IASP (Merskey and Bogduk) definition [27]: chronic pain that is 
‘‘initiated or caused by a primary lesion or dysfunction in the nervous system.’’ This definition has since been 
superseded as pain ‘‘arising as a direct consequence of a lesion or disease affecting the somatosensory system’’ 
[20,25]. 
Although case ascertainment tools were used by a number of studies, these were neither designed to nor did they 
claim to make a diagnosis of definite neuropathic pain; rather they were validated in identifying pain with 
neuropathic characteristics [5]. Some studies were clear in their acknowledgment of this in describing the cases 
[4,35,38,42], but other studies did not distinguish between neuropathic features and neuropathic pain [8,15]. 
In studies based on reviews of medical records, the identification of cases relies on accurate diagnoses of 
neuropathic pain (conditions) by the physician, who then must enter details accurately, using an accurate coding 
system and an accurate method of retrieving these codes. Rates calculated from medical records also may be 
affected by severity of pain or disease, as patients with more severe cases are more likely to seek medical attention 
[37]. Factors that may affect incidence and prevalence rate estimates (in general) are summarised in Table 5. 
Although there are published guidelines on the assessment of neuropathic pain [17], the lack of an agreed-upon 
specific diagnostic tool has resulted in a proposed grading system of definite, probable, and possible neuropathic 
pain [20]. This is based on a combination of plausible distribution and history of pain, other positive confirmatory 
tests, and clinical investigation(s) by a pain specialist or neurologist [39]. For large epidemiological studies, the  
 
 
 
 
 
grading of probable or definite neuropathic pain is not practicable to achieve, and at best the case definitions 
included in this review may approximate possible neuropathic pain. Existing Special Interest Group on 
Neuropathic Pain (NeuPSIG) guidelines on neuropathic pain assessment advise that existing screening tools 
require further validation before they can be completely useful for epidemiological studies in general population 
samples [16]. Further research should look to explore how the findings of these questionnaire-based screening 
instruments/case ascertainment tools relate to specialist clinical examinations in a general population sample. 
Neuropathic pain is associated with a number of clinical conditions and diseases, but only a small number of them 
were examined in the articles identified for inclusion in this review. Particular aetiologies such as PHN were more 
commonly studied, whereas others such as spinal cord injury [33] were not studied in a general population 
context. Published studies of the epidemiology of these less common subgroups tended to be conducted in small 
samples, in specialist settings, or in secondary care, providing an indication of their likelihood in these subgroups, 
but not of the overall population burden or risk. 
 
 
 
Table 5 
Summary of the factors influencing reported incidence and prevalence rates of neuropathic pain. 
 
 
• Definitions of neuropathic pain or pain with neuropathic characteristics 
• Definitions of clinical conditions/diseases associated with neuropathic pain 
• Case ascertainment methods 
• Case ascertainment tools (eg,screening tools vs cases coded from elec tronic databases) 
• Severity of neuropathic pain 
     • Accuracy of recording and coding in medical records  
 
 
4.3. Strengths and weaknesses 
 
The strengths of this review are in its strict systematic approach and consistency in application of the criteria 
throughout. A thorough search strategy was developed. The studies included were all of medium to high 
quality. 
Although a number of the screening tools that identify pain with neuropathic characteristics have been 
translated and validated for use in other languages [29], a limitation in this review was the exclusion of non-
English-language articles, as translation was beyond the available resources. 
Unlike other systematic reviews [28,31], there is no recognised quality checklist pertaining to observational 
studies within the general population. Hence a quality checklist was developed from a well-used standard tool 
specifically for epidemiological studies [40]. Although it is not a standard instrument for systematic reviews, it 
does provide a reasonable indicator of quality and validity, allowing rejection of articles or studies of low 
quality and comparison between studies. 
 
4.4. Implications for research and clinical practice 
 
As the use of screening tools within the published literature increases, it may be possible to restrict a 
future review to a specified case ascertainment tool, eg, DN4 or S-LANSS. The studies included would 
therefore have greater consistency, would have similar features in common, and would be more comparable 
when analysing the results. 
Now that there is an agreed-upon definition of neuropathic pain, it is important to acknowledge its 
limitations and the application of this within large epidemiological studies. There is also a good argument that 
neuropathic pain should be considered as a Medical Subject Headings (MeSH) term in databases. 
 
4.5. Conclusions 
 
A comprehensive literature search and systematic review was performed on the epidemiology of 
neuropathic pain in the general population. A range of incidence and prevalence rates has been identified. The 
lack of consensus on a definition, diagnostic criteria, and appropriate and consistent use of the screening tools 
are reflected by the varying methods and results of the studies included in this review. Future epidemiological 
studies into neuropathic pain within the community should take note of these factors, using a standardised 
approach for identifying pain with possible neuropathic features. 
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